BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Copy of Newspaper Publication.
BALAXI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Balaxi Pharmaceuticals published its audited standalone and consolidated financial results for Q4 FY26 and full year ended March 31, 2026 in Business Standard (English) and Nava Telangana (Telugu) newspapers on May 30, 2026. The publication was done within 48 hours of the Board meeting held on May 28, 2026, as required under SEBI regulations. Standalone total income for FY26 was Rs 27,017.35 lakhs, with net profit after tax at Rs 905.74 lakhs. However, Q4 standalone net profit after tax was only Rs 15.81 lakhs, a sharp decline from Rs 360.13 lakhs in Q4 FY25, indicating a significant drop in quarterly profitability. Equity share capital is Rs 1,104.15 lakhs with face value of Rs 10 per share. The results are prepared in accordance with Indian Accounting Standards (Ind AS).
The sharp decline in Q4 standalone net profit (from Rs 360 lakhs to Rs 16 lakhs) is a concern for investors, though full-year profit of Rs 906 lakhs remains positive. The company met regulatory compliance for timely disclosure.